Digital writing solution speeds up data harvest while ensuring traceability and capture ease
Digital writing solution speeds up data harvest while ensuring traceability and capture ease
Kayentis (Paris, France) is out with a digital pen and paper technology product, called Clin'Form, designed to streamline handwritten entry of clinical trial data into an electronic CRF through a collaborative, Web-based portal. The product is based on the Forms Automation System architecture using the Anoto Digital Pen & Paper technology.
Clin'Form enables a complete audit trail with full information traceability for data captured with digital pens. Also, tracking key users, including trial investigators, CRAs, and data managers, is possible, as well as study progress reports in real time on such measures as center openings, patient inclusion rates, and CRF completion follow-up. Once collected, Clin'Form facilitates the push of data to clinical data management systems in CDISC-compatible format, adding to its versatility.
Kayentis, (609) 627-5300, www.kayentis.fr
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.